Median progression-free survival ( primary end point ) for axitinib ( N = @ ) and bevacizumab ( N = @ ) , respectively , was @ and @ months -LSB- hazard ratio ( HR ) @ , @ % confidence interval ( CI ) @-@ @ ; one-sided stratified P = @ -RSB- ; median overall survival was @ and @ months ( HR @ , @ % CI @-@ @ ; one-sided stratified P = @ ) .